NCT01165008已完成2 期
Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies.
Patients and methods: Fifteen patients with refractory polymyositis (PM), dermatomyositis (DM), or inclusion body myositis (IBM) were treated with 100 mg anakinra subcutaneously per day during 12 months. Outcome measures included myositis disease activity score with improvement defined according to The International Myositis Assessment and Clinical Studies Group (IMACS) and for muscle performance the functional index of myositis (FI). In addition repeat muscle biopsies were performed
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women aged 18 to 80 years with diagnosis of PM, DM or IBM based Peter and Bohan's and Grigg's criteria. All patients had to be capable of giving informed consent. Other inclusion criteria were muscle strength and/or function reduced at least 20 % below predicted values as measured by functional index (FI) [45-47] and failure to respond to treatment with high-dose glucocorticoids (0.75 mg/kg/day for at least one month) in combination with azathioprine and/or methotrexate for at least two months.
排除标准
- •serious infections such as hepatitis, pneumonia, pyelonephritis in the previous 3 months; history of opportunistic infections such as tuberculosis, drug resistant atypical mycobacterium, active pneumocystis carinii, active cytomegalovirus infection; documented HIV infection; alcoholism, alcoholic liver disease or other chronic liver disease; chest x-ray suggestive of active tuberculosis; and pregnant, nursing mothers or patients with planned pregnancy within one and a half years of enrolment.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Effect of anakinra (soluble interleukin-1 receptor antagonist) as combination therapy: second UK combination therapy in early rheumatoid arthritisMusculoskeletal DiseasesRheumatoid arthritisISRCTN15819795King's College London (UK)158
终止
1 期
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory DiseaseNervous System MalformationsArthropathy, NeurogenicPapilledemaUrticariaNCT00069329National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)43
终止
1 期
Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing LossHearing Loss, SuddenNCT02414152Andrea Vambutas2
已完成
1 期
A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear DiseaseSensorineural Hearing LossAutoimmune Inner Ear DiseaseNCT01267994Andrea Vambutas13
进行中（未招募）
2 期
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell TherapyB Cell ALLB-cell Non Hodgkin LymphomaB-Cell LymphomaNCT04148430Memorial Sloan Kettering Cancer Center62